Mazdutide
Mazdutide attacks fat from two angles: GLP-1 receptor activation suppresses appetite while glucagon receptor activation drives direct fat oxidation. It's particularly effective against liver fat (NAFLD/NASH), making it the go-to for researchers studying metabolic syndrome with hepatic involvement. The Chinese-developed Ozempic competitor making waves in clinical trials.
About Mazdutide
Mazdutide represents an emerging class of dual-action metabolic peptides. OXM is a naturally occurring gut hormone that activates both GLP-1R and GCGR, but with a short half-life limiting its therapeutic potential. Mazdutide is engineered for extended duration while preserving dual receptor activity. Clinical research has demonstrated effects on body weight, glycemic parameters, and hepatic steatosis markers. It is under active investigation in Phase 3 clinical trials for obesity and type 2 diabetes.
Full Research Monograph — 4 PubMed CitationsYou May Also Consider
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
Retatrutide 12mg
12mgThe most powerful weight loss compound ever studied — triple-receptor agonist that achieved 24% body weight loss in trials, outperforming semaglutide by hitting THREE metabolic pathways.
- Triple-action weight loss — targets GLP-1, GIP, AND glucagon receptors
- 24% body weight loss in trials — MORE than semaglutide
Cagrilintide
5mgThe semaglutide amplifier — a long-acting amylin that pairs with GLP-1 drugs to supercharge weight loss. Part of the CagriSema combination that's the next breakthrough.
- Long-acting amylin analog for appetite suppression
- Pairs with semaglutide for enhanced weight loss (CagriSema)